Teva Pharmaceutical Industries (NYSE:TEVA) Rating Lowered to Hold at Wall Street Zen

Teva Pharmaceutical Industries (NYSE:TEVA) was downgraded by equities researchers at Wall Street Zen from a “buy” rating to a “hold” rating in a note issued to investors on Sunday.

TEVA has been the topic of a number of other research reports. UBS Group increased their price target on Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. Truist Financial upped their target price on Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Monday, April 20th. Piper Sandler reissued an “overweight” rating and issued a $42.00 price target (up from $41.00) on shares of Teva Pharmaceutical Industries in a research note on Thursday, April 30th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock an “overweight” rating in a report on Thursday, April 30th. Nine equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $41.78.

Teva Pharmaceutical Industries Price Performance

Shares of Teva Pharmaceutical Industries stock traded down $0.28 during trading hours on Friday, reaching $32.82. The stock had a trading volume of 6,638,115 shares, compared to its average volume of 5,223,980. The stock’s 50 day moving average is $34.14 and its 200 day moving average is $32.68. The company has a current ratio of 1.01, a quick ratio of 0.78 and a debt-to-equity ratio of 1.70. Teva Pharmaceutical Industries has a twelve month low of $14.99 and a twelve month high of $37.35. The firm has a market capitalization of $37.74 billion, a PE ratio of 24.68, a PEG ratio of 4.02 and a beta of 0.86.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Tuesday, March 31st. The company reported $0.53 EPS for the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%.The firm had revenue of $3.98 billion for the quarter. Equities analysts expect that Teva Pharmaceutical Industries will post 1.97 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Teva Pharmaceutical Industries news, CAO Amir Weiss sold 10,679 shares of the business’s stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $36.00, for a total transaction of $384,444.00. Following the completion of the sale, the chief accounting officer directly owned 20,016 shares in the company, valued at approximately $720,576. The trade was a 34.79% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Eliyahu Sharon Kalif sold 106,563 shares of the stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $34.10, for a total value of $3,633,798.30. Following the transaction, the executive vice president directly owned 65,621 shares of the company’s stock, valued at $2,237,676.10. The trade was a 61.89% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 465,931 shares of company stock worth $16,332,989 in the last quarter. 0.54% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in TEVA. Victrix Investment Advisors lifted its holdings in Teva Pharmaceutical Industries by 9.5% in the 2nd quarter. Victrix Investment Advisors now owns 7,850 shares of the company’s stock valued at $266,000 after purchasing an additional 681 shares in the last quarter. Assenagon Asset Management S.A. grew its holdings in shares of Teva Pharmaceutical Industries by 128.1% during the second quarter. Assenagon Asset Management S.A. now owns 3,056,017 shares of the company’s stock worth $103,538,000 after buying an additional 1,716,315 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Teva Pharmaceutical Industries by 19.6% during the second quarter. GAMMA Investing LLC now owns 11,361 shares of the company’s stock worth $385,000 after buying an additional 1,859 shares in the last quarter. Versant Capital Management Inc raised its position in shares of Teva Pharmaceutical Industries by 15.8% in the second quarter. Versant Capital Management Inc now owns 10,265 shares of the company’s stock valued at $348,000 after buying an additional 1,399 shares during the last quarter. Finally, CX Institutional acquired a new stake in shares of Teva Pharmaceutical Industries in the second quarter valued at about $54,000. 54.05% of the stock is owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.